The Experts below are selected from a list of 5445 Experts worldwide ranked by ideXlab platform

Anne M Wallace - One of the best experts on this subject based on the ideXlab platform.

  • Comparison of Post-Injection Site Pain Between Technetium Sulfur Colloid and Technetium Tilmanocept in Breast Cancer Patients Undergoing Sentinel Lymph Node Biopsy.
    Annals of surgical oncology, 2015
    Co-Authors: Jonathan T Unkart, Jennifer L Baker, Ava Hosseini, Carl K Hoh, Mark S Wallace, David R Vera, Anne M Wallace
    Abstract:

    No prior studies have examined Injection Pain associated with Technetium-99m Tilmanocept (TcTM). This was a randomized, double-blinded study comparing postInjection Site Pain between filtered Technetium Sulfur Colloid (fTcSC) and TcTM in breast cancer lymphoscintigraphy. Pain was evaluated with a visual analogue scale (VAS) (0-100 mm) and the short-form McGill Pain Questionnaire (SF-MPQ). The primary endpoint was mean difference in VAS scores at 1-min postInjection between fTcSC and TcTM. Secondary endpoints included a comparison of SF-MPQ scores between the groups at 5 min postInjection and construction of a linear mixed effects model to evaluate the changes in Pain during the 5-min postInjection period. Fifty-two patients underwent Injection (27-fTcSC, 25-TcTM). At 1-min postInjection, patients who received fTcSC experienced a mean change in Pain of 16.8 mm (standard deviation (SD) 19.5) compared with 0.2 mm (SD 7.3) in TcTM (p = 0.0002). At 5 min postInjection, the mean total score on the SF-MPQ was 2.8 (SD 3.0) for fTcSC versus 2.1 (SD 2.5) for TcTM (p = 0.36). In the mixed effects model, Injection agent (p < 0.001), time (p < 0.001) and their interaction (p < 0.001) were associated with change in Pain during the 5-min postInjection period. The model found fTcSC resulted in significantly more Pain of 15.2 mm (p < 0.001), 11.3 mm (p = 0.001), and 7.5 mm (p = 0.013) at 1, 2, and 3 min postInjection, respectively. Injection with fTcSC causes significantly more Pain during the first 3 min postInjection compared with TcTM in women undergoing lymphoscintigraphy for breast cancer.

  • Comparison of Post-Injection Site Pain Between Technetium Sulfur Colloid and Technetium Tilmanocept in Breast Cancer Patients Undergoing Sentinel Lymph Node Biopsy
    Annals of Surgical Oncology, 2015
    Co-Authors: Jonathan T Unkart, Jennifer L Baker, Ava Hosseini, Carl K Hoh, Mark S Wallace, David R Vera, Anne M Wallace
    Abstract:

    Background No prior studies have examined Injection Pain associated with Technetium-99m Tilmanocept (TcTM).

Jonathan T Unkart - One of the best experts on this subject based on the ideXlab platform.

  • Comparison of Post-Injection Site Pain Between Technetium Sulfur Colloid and Technetium Tilmanocept in Breast Cancer Patients Undergoing Sentinel Lymph Node Biopsy.
    Annals of surgical oncology, 2015
    Co-Authors: Jonathan T Unkart, Jennifer L Baker, Ava Hosseini, Carl K Hoh, Mark S Wallace, David R Vera, Anne M Wallace
    Abstract:

    No prior studies have examined Injection Pain associated with Technetium-99m Tilmanocept (TcTM). This was a randomized, double-blinded study comparing postInjection Site Pain between filtered Technetium Sulfur Colloid (fTcSC) and TcTM in breast cancer lymphoscintigraphy. Pain was evaluated with a visual analogue scale (VAS) (0-100 mm) and the short-form McGill Pain Questionnaire (SF-MPQ). The primary endpoint was mean difference in VAS scores at 1-min postInjection between fTcSC and TcTM. Secondary endpoints included a comparison of SF-MPQ scores between the groups at 5 min postInjection and construction of a linear mixed effects model to evaluate the changes in Pain during the 5-min postInjection period. Fifty-two patients underwent Injection (27-fTcSC, 25-TcTM). At 1-min postInjection, patients who received fTcSC experienced a mean change in Pain of 16.8 mm (standard deviation (SD) 19.5) compared with 0.2 mm (SD 7.3) in TcTM (p = 0.0002). At 5 min postInjection, the mean total score on the SF-MPQ was 2.8 (SD 3.0) for fTcSC versus 2.1 (SD 2.5) for TcTM (p = 0.36). In the mixed effects model, Injection agent (p < 0.001), time (p < 0.001) and their interaction (p < 0.001) were associated with change in Pain during the 5-min postInjection period. The model found fTcSC resulted in significantly more Pain of 15.2 mm (p < 0.001), 11.3 mm (p = 0.001), and 7.5 mm (p = 0.013) at 1, 2, and 3 min postInjection, respectively. Injection with fTcSC causes significantly more Pain during the first 3 min postInjection compared with TcTM in women undergoing lymphoscintigraphy for breast cancer.

  • Comparison of Post-Injection Site Pain Between Technetium Sulfur Colloid and Technetium Tilmanocept in Breast Cancer Patients Undergoing Sentinel Lymph Node Biopsy
    Annals of Surgical Oncology, 2015
    Co-Authors: Jonathan T Unkart, Jennifer L Baker, Ava Hosseini, Carl K Hoh, Mark S Wallace, David R Vera, Anne M Wallace
    Abstract:

    Background No prior studies have examined Injection Pain associated with Technetium-99m Tilmanocept (TcTM).

David R Vera - One of the best experts on this subject based on the ideXlab platform.

  • Comparison of Post-Injection Site Pain Between Technetium Sulfur Colloid and Technetium Tilmanocept in Breast Cancer Patients Undergoing Sentinel Lymph Node Biopsy.
    Annals of surgical oncology, 2015
    Co-Authors: Jonathan T Unkart, Jennifer L Baker, Ava Hosseini, Carl K Hoh, Mark S Wallace, David R Vera, Anne M Wallace
    Abstract:

    No prior studies have examined Injection Pain associated with Technetium-99m Tilmanocept (TcTM). This was a randomized, double-blinded study comparing postInjection Site Pain between filtered Technetium Sulfur Colloid (fTcSC) and TcTM in breast cancer lymphoscintigraphy. Pain was evaluated with a visual analogue scale (VAS) (0-100 mm) and the short-form McGill Pain Questionnaire (SF-MPQ). The primary endpoint was mean difference in VAS scores at 1-min postInjection between fTcSC and TcTM. Secondary endpoints included a comparison of SF-MPQ scores between the groups at 5 min postInjection and construction of a linear mixed effects model to evaluate the changes in Pain during the 5-min postInjection period. Fifty-two patients underwent Injection (27-fTcSC, 25-TcTM). At 1-min postInjection, patients who received fTcSC experienced a mean change in Pain of 16.8 mm (standard deviation (SD) 19.5) compared with 0.2 mm (SD 7.3) in TcTM (p = 0.0002). At 5 min postInjection, the mean total score on the SF-MPQ was 2.8 (SD 3.0) for fTcSC versus 2.1 (SD 2.5) for TcTM (p = 0.36). In the mixed effects model, Injection agent (p < 0.001), time (p < 0.001) and their interaction (p < 0.001) were associated with change in Pain during the 5-min postInjection period. The model found fTcSC resulted in significantly more Pain of 15.2 mm (p < 0.001), 11.3 mm (p = 0.001), and 7.5 mm (p = 0.013) at 1, 2, and 3 min postInjection, respectively. Injection with fTcSC causes significantly more Pain during the first 3 min postInjection compared with TcTM in women undergoing lymphoscintigraphy for breast cancer.

  • Comparison of Post-Injection Site Pain Between Technetium Sulfur Colloid and Technetium Tilmanocept in Breast Cancer Patients Undergoing Sentinel Lymph Node Biopsy
    Annals of Surgical Oncology, 2015
    Co-Authors: Jonathan T Unkart, Jennifer L Baker, Ava Hosseini, Carl K Hoh, Mark S Wallace, David R Vera, Anne M Wallace
    Abstract:

    Background No prior studies have examined Injection Pain associated with Technetium-99m Tilmanocept (TcTM).

Mark S Wallace - One of the best experts on this subject based on the ideXlab platform.

  • Comparison of Post-Injection Site Pain Between Technetium Sulfur Colloid and Technetium Tilmanocept in Breast Cancer Patients Undergoing Sentinel Lymph Node Biopsy.
    Annals of surgical oncology, 2015
    Co-Authors: Jonathan T Unkart, Jennifer L Baker, Ava Hosseini, Carl K Hoh, Mark S Wallace, David R Vera, Anne M Wallace
    Abstract:

    No prior studies have examined Injection Pain associated with Technetium-99m Tilmanocept (TcTM). This was a randomized, double-blinded study comparing postInjection Site Pain between filtered Technetium Sulfur Colloid (fTcSC) and TcTM in breast cancer lymphoscintigraphy. Pain was evaluated with a visual analogue scale (VAS) (0-100 mm) and the short-form McGill Pain Questionnaire (SF-MPQ). The primary endpoint was mean difference in VAS scores at 1-min postInjection between fTcSC and TcTM. Secondary endpoints included a comparison of SF-MPQ scores between the groups at 5 min postInjection and construction of a linear mixed effects model to evaluate the changes in Pain during the 5-min postInjection period. Fifty-two patients underwent Injection (27-fTcSC, 25-TcTM). At 1-min postInjection, patients who received fTcSC experienced a mean change in Pain of 16.8 mm (standard deviation (SD) 19.5) compared with 0.2 mm (SD 7.3) in TcTM (p = 0.0002). At 5 min postInjection, the mean total score on the SF-MPQ was 2.8 (SD 3.0) for fTcSC versus 2.1 (SD 2.5) for TcTM (p = 0.36). In the mixed effects model, Injection agent (p < 0.001), time (p < 0.001) and their interaction (p < 0.001) were associated with change in Pain during the 5-min postInjection period. The model found fTcSC resulted in significantly more Pain of 15.2 mm (p < 0.001), 11.3 mm (p = 0.001), and 7.5 mm (p = 0.013) at 1, 2, and 3 min postInjection, respectively. Injection with fTcSC causes significantly more Pain during the first 3 min postInjection compared with TcTM in women undergoing lymphoscintigraphy for breast cancer.

  • Comparison of Post-Injection Site Pain Between Technetium Sulfur Colloid and Technetium Tilmanocept in Breast Cancer Patients Undergoing Sentinel Lymph Node Biopsy
    Annals of Surgical Oncology, 2015
    Co-Authors: Jonathan T Unkart, Jennifer L Baker, Ava Hosseini, Carl K Hoh, Mark S Wallace, David R Vera, Anne M Wallace
    Abstract:

    Background No prior studies have examined Injection Pain associated with Technetium-99m Tilmanocept (TcTM).

Carl K Hoh - One of the best experts on this subject based on the ideXlab platform.

  • Comparison of Post-Injection Site Pain Between Technetium Sulfur Colloid and Technetium Tilmanocept in Breast Cancer Patients Undergoing Sentinel Lymph Node Biopsy.
    Annals of surgical oncology, 2015
    Co-Authors: Jonathan T Unkart, Jennifer L Baker, Ava Hosseini, Carl K Hoh, Mark S Wallace, David R Vera, Anne M Wallace
    Abstract:

    No prior studies have examined Injection Pain associated with Technetium-99m Tilmanocept (TcTM). This was a randomized, double-blinded study comparing postInjection Site Pain between filtered Technetium Sulfur Colloid (fTcSC) and TcTM in breast cancer lymphoscintigraphy. Pain was evaluated with a visual analogue scale (VAS) (0-100 mm) and the short-form McGill Pain Questionnaire (SF-MPQ). The primary endpoint was mean difference in VAS scores at 1-min postInjection between fTcSC and TcTM. Secondary endpoints included a comparison of SF-MPQ scores between the groups at 5 min postInjection and construction of a linear mixed effects model to evaluate the changes in Pain during the 5-min postInjection period. Fifty-two patients underwent Injection (27-fTcSC, 25-TcTM). At 1-min postInjection, patients who received fTcSC experienced a mean change in Pain of 16.8 mm (standard deviation (SD) 19.5) compared with 0.2 mm (SD 7.3) in TcTM (p = 0.0002). At 5 min postInjection, the mean total score on the SF-MPQ was 2.8 (SD 3.0) for fTcSC versus 2.1 (SD 2.5) for TcTM (p = 0.36). In the mixed effects model, Injection agent (p < 0.001), time (p < 0.001) and their interaction (p < 0.001) were associated with change in Pain during the 5-min postInjection period. The model found fTcSC resulted in significantly more Pain of 15.2 mm (p < 0.001), 11.3 mm (p = 0.001), and 7.5 mm (p = 0.013) at 1, 2, and 3 min postInjection, respectively. Injection with fTcSC causes significantly more Pain during the first 3 min postInjection compared with TcTM in women undergoing lymphoscintigraphy for breast cancer.

  • Comparison of Post-Injection Site Pain Between Technetium Sulfur Colloid and Technetium Tilmanocept in Breast Cancer Patients Undergoing Sentinel Lymph Node Biopsy
    Annals of Surgical Oncology, 2015
    Co-Authors: Jonathan T Unkart, Jennifer L Baker, Ava Hosseini, Carl K Hoh, Mark S Wallace, David R Vera, Anne M Wallace
    Abstract:

    Background No prior studies have examined Injection Pain associated with Technetium-99m Tilmanocept (TcTM).